Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in MAS associated with sJIA or AOSD
NCT03311854Phase 2Completed
- Sponsor
- Sobi
- Start
- Feb 2018
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of emapalumab in macrophage activation syndrome (MAS), sponsored by Sobi. Started Feb 2018; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on NCT03311854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311854.